Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P31749 (
AKT
)
22,954
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
Serine incorporator 2
(
SERINC2
) is a member of the SERINC family of transmembrane proteins that incorporate serine into membrane lipids during synthesis. In the present study, the biological function of
SERINC2
in lung adenocarcinoma cells was investigated. The data from a previous study and the publicly available Oncomine database were analysed regarding the expression levels of
SERINC2
mRNA in lung adenocarcinoma. A lentiviral-based short hairpin RNA (shRNA) was used to suppress
SERINC2
expression in lung cancer cells. The effect of
SERINC2
expression on lung cancer proliferation was determined using cell counting kit-8 and colony formation assays. The influence on invasion and migration was examined
in vitro
using Transwell and wound-healing assays, respectively. Phosphorylated protein kinase B (p-
AKT
) expression levels were assessed by immunoblotting. According to a previous study and Oncomine, expression levels of
SERINC2
mRNA are significantly upregulated in tumour tissues compared with those in healthy tissues in patients with lung adenocarcinoma.
SERINC2
-knockdown by lentiviral-based shRNA inhibited the proliferation, migration and invasion of the H1650 and A549 cells. In addition, p-
AKT
expression levels were significantly decreased following
SERINC2
-knockdown. In conclusion,
SERINC2
-knockdown suppresses lung adenocarcinoma proliferation, migration and invasion through a mechanism that may be associated with phosphatidylinositol 3-kinase/
AKT
signalling. Based on these findings,
SERINC2
serves an important role in the progression of lung adenocarcinoma.
...
PMID:SERINC2-knockdown inhibits proliferation, migration and invasion in lung adenocarcinoma. 3040 54